Speaker Program
INVITATION

You are cordially invited to attend a Speaker Program on VELTASSA® (patiromer) For Oral Suspension.

VELTASSA: A Paradigm Shift in the Treatment of Hyperkalemia

Arvind Madan, MD

Nephrologist
Nephrology Associates of Central Florida
Orlando, FL

Capital Grille

11365 Legacy Ave.
Palm Beach Gardens, FL 33410
561.630.4994

Thursday, April 26, 2018 at 6:30 PM

Please RSVP by April 21, 2018 to
Margie DeCanio at mdecanio@relypsa.com
or via phone at 561-665-0440

INDICATION AND USE:

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

IMPORTANT SAFETY INFORMATION:

Contraindication: Patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnesemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.

Adverse Reactions: The most common adverse reactions (incidence ≥ 2%) are constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort and flatulence. Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.

Please see accompanying full Prescribing Information

IMPORTANT NOTE:

HCPs are encouraged but not required to bring their National Provider Identifier (NPI) and/or a State License Number (SLN) to the program. This information will only be used for reporting purposes. You may look up your NPI and SLN at: https://npidb.org/npi-lookup/.

Relypsa complies with all federal and state reporting requirements. As required, meals and beverages provided and accepted by HCPs may be subject to reporting. Relypsa will neither recommend, endorse, nor support the submission of this promotional program for CME credits.

If you wish to stop receiving communications from Relypsa regarding promotional speaker programs, please send an email with UNSUBSCRIBE in the subject or body to: VeltassaPrograms@insyght.com.

relypsa
A Vifor Pharma Group Company